The Treatment of Traumatised Refugees With Sertraline Versus Venlafaxine in Combination With Psychotherapy
NCT01569685 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 207
Last updated 2015-03-04
Summary
Background: The treatment of traumatised refugees is one of the areas within the field of psychiatry with the weakest evidence for the different types of treatment. This is a problem for both patients and doctors as well as for society.
The treatment of choice today for Post Traumatic Stress disorder (PTSD) is antidepressants from the subgroup of Selektive Serotonin Reuptake Inhibitors (SSRI), among these the drug Sertraline. The evidence for the use of these drugs as treatment for chronically complex PTSD in traumatised refugees is however very limited and a large part of the group is estimated to be insufficiently treated with this type of medicine. Venlafaxine is an antidepressant from the subgroup of dual action product which means that is works on several pathways in the brain. Among others it influences the area in the brain that is responsible for the enhanced anxiety and hyperarousal experienced by traumatised refugees and which is found to be enlarged among patients suffering from PTSD.
All together there is not sufficient evidence to conclude which type of medical and psychological treatment that is most efficient when it comes to the treatment of traumatised refugees. Also there is a lack of studies which examines social functioning and the relation between psychosocial resources and outcome from treatment. Furthermore there is a lack of knowledge of predictors of treatment outcome for the individual patients. This study seeks to produce some of this evidence.
Method: This study is expected to include approximately 150 patients randomised into two different groups. The patients are treated with Setraline or Venlafaxine depending on the group the randomised to. Patients in both groups are getting the same version of manual based Cognitive Behavioural Therapy that is specially adapted to this group of patients. The treatment period is 6-7 month. The trial endpoints are PTSD-and depression symptoms and social functioning all measured on internationally validated ratings scales.
Furthermore the study will examine the relation between expected outcome of treatment from a range of predictors and the actual treatment results for the individual patient.
Results: Altogether this study will bring forward new standards for clinical evaluation and treatment of traumatised refugees and the results are expected to be used in reference programmes/clinical guidelines.
Conditions
- Post Traumatic Stress Disorder
- Depression
Interventions
- DRUG
-
Venlafaxine
Tablets, once a day, max 375 mg day (maximal recommended dose)
- DRUG
-
Sertraline
Tablets, once a day, maximum 200 mg/day (maximum required dose)
Sponsors & Collaborators
-
Psychiatric Center Ballerup
collaborator OTHER -
Charlotte Sonne
lead OTHER
Principal Investigators
-
Charlotte K Sonne, MD · Psychiatric Center Ballerup
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-04-30
- Primary Completion
- 2014-10-31
- Completion
- 2014-10-31
Countries
- Denmark
Study Locations
More Related Trials
-
Combination Therapy in Patients With Depression
NCT00485862 ·Status: COMPLETED ·Phase: PHASE4
-
A Comparison of Sertraline-reboxetine Combination Therapy Versus Sertraline or Reboxetine Monotherapy in the Treatment of Major Depression.
NCT00636246 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Stress Disorders
NCT00050804 ·Status: COMPLETED ·Phase: PHASE4
-
Acute Effectiveness of Additional Drugs to the Standard Treatment of Depression
NCT00001483 ·Status: COMPLETED ·Phase: PHASE2
-
Predicting SSRI Efficacy in Veterans With PTSD
NCT04183205 ·Status: TERMINATED ·Phase: PHASE4
-
Treatment of Depressed Women Who Have Been Sexually Abused
NCT00042237 ·Status: COMPLETED ·Phase: PHASE1
-
Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms
NCT00169988 ·Status: COMPLETED ·Phase: NA
-
Combination Treatment Study for Memory Impairment and Depression
NCT01658228 ·Status: COMPLETED ·Phase: PHASE4
-
Interpersonal Psychotherapy for Treatment Resistant Depression
NCT01896349 ·Status: UNKNOWN ·Phase: NA
-
SSRI Administration to Reduce Acute Stress Disorder Symptoms and Prevent Depression and PTSD in Physical Trauma Victims
NCT00114374 ·Status: TERMINATED ·Phase: PHASE3
-
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
NCT04532749 ·Status: TERMINATED ·Phase: PHASE3
-
Repetitive Behavior Disorders in People With Severe Mental Retardation
NCT00491478 ·Status: UNKNOWN ·Phase: PHASE3
-
Sertraline vs. Placebo for Symptoms Following Traumatic Brain Injury
NCT00208585 ·Status: UNKNOWN ·Phase: NA
-
Treatment of Postpartum Depression With Psychotherapy and Add-on Sertraline
NCT01028482 ·Status: COMPLETED ·Phase: NA
-
Mindfulness Based Cognitive Therapy and Antidepressant Medication in Recurrent Depression
NCT00928980 ·Status: COMPLETED ·Phase: NA
-
Evaluating the Effectiveness of Sertraline in Treating Women With Premenstrual Dysphoric Disorder
NCT00536198 ·Status: COMPLETED ·Phase: PHASE4
-
Antidepressant Discontinuation in Treatment Resistant Depression
NCT03786614 ·Status: UNKNOWN ·Phase: NA
-
Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence
NCT00330239 ·Status: COMPLETED ·Phase: PHASE4
-
Open-Label Duloxetine Monotherapy in the Treatment of Posttraumatic Stress Disorder
NCT00583193 ·Status: UNKNOWN ·Phase: PHASE3
-
Discontinuation of Antidepressant Medication in Primary Care.
NCT03361514 ·Status: COMPLETED ·Phase: NA
-
Citalopram vs Clomipramine vs Placebo in Recurrent Depression
NCT01575158 ·Status: COMPLETED ·Phase: NA
-
Compare the Efficacy and Tolerability of the Combination of Aripiprazole and Selective Serotonin Reuptake Inhibitors (SSRIs) Used in Major Depression
NCT00873795 ·Status: COMPLETED ·Phase: NA
-
Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Major Depressive Disorder
NCT00143091 ·Status: TERMINATED ·Phase: PHASE2
-
An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression
NCT00256113 ·Status: COMPLETED ·Phase: PHASE3
-
A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression {ASCEND}
NCT02358343 ·Status: COMPLETED ·Phase: PHASE3